Smart Pills Market: Growth, Size, Share, and Trends
Smart Pills Market by Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring), Target Area (Esophagus, Small Intestine, Large Intestine, Stomach), End User (Hospitals, Diagnostic Centers), and Region - Global Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global smart pills market is projected to reach USD 1.30 billion by 2030 from USD 0.69 billion in 2024, at a CAGR of 11.2% during the forecast period. The key factors driving the market growth include technological advancements and innovative healthcare developments.
KEY TAKEAWAYS
-
By RegionNorth America accounted for the largest share of 53.7% of the smart pills market in 2023.
-
By Target AreaThe small intestine segment accounted for the largest share of 58.5% in 2023, owing to the increasing incidence of small intestine disorders such as Crohn's disease, celiac disorders, and small bowel tumours.
-
By ApplicationThe capsule endoscopy segment is expected to grow at a higher CAGR of 10.8% during the forecast period because capsule endoscopy has become a widely adopted technique for assessing obscure GI bleeding, Crohn's disease, small bowel tumors, and polyposis syndrome.
-
By Disease IndicationThe occult GI bleeding segment accounted for the largest share in 2023, owing to the increasing disease prevalence, growing demand for non-invasive diagnostics, and rising technological advancements in smart pill technologies.
-
By End-use ApplicationHospitals are the largest end user segment in 2023, with an expected growth at a CAGR of 10.7% during the forecast period. The highest share of this segment can be attributed to the rising preference for minimally invasive surgical procedures and the rising incidence of colon cancer.
The pills are equipped with sensors, microprocessors, and wireless communication features and have revolutionized patient care through miniaturization, longer battery life, and improved data processing of pills for disease diagnosis. Furthermore, the pills meet critical healthcare needs by providing a non-invasive, convenient solution for tracking vital signs, ensuring medication adherence, and diagnosing gastrointestinal disorders. These pills enhance patient outcomes and reduce healthcare costs, signifying a significant advancement in modern medicine
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The smart pills market is being reshaped by rapid advances in micro-sensor technology, AI-powered diagnostics, and wireless data transmission, shifting diagnostics from hospital-based to inside-the-body monitoring. These innovations are disrupting traditional endoscopy and imaging workflows by offering non-invasive, patient-friendly alternatives with real-time insights. Pharma-tech convergence is enabling smart pills not just for diagnosis but also for targeted drug delivery, creating new business models and regulatory pathways. As reimbursement policies evolve and remote care platforms integrate ingestible devices, the market is moving from niche adoption to mainstream clinical use.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising demand for non-invasive diagnostic monitoring devices
-
Technological advancements in capsule endoscopy
Level
-
High R&D costs for technological developments and advancements
-
Low accuracy and reliability of sensors and cameras in smart pills
Level
-
Innovations in sensor technologies and wireless communication
-
Rising need for rapid drug delivery and development
Level
-
Increased patient privacy and data security concerns
-
Shortage of skilled healthcare professionals
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Technological advancements in capsule endoscopy
Capsule endoscopy is a major advancement in the field of endoscopy and is rapidly replacing GI video scopes. Until the development of capsule endoscopy, the complete evaluation of the small bowel was complicated, making smart pills a disruptive technology that can revolutionize the diagnosis of small bowel diseases. Capsule endoscopy procedures are patient-friendly and provide a detailed view of the small bowel mucosa. The market has witnessed significant advancements in capsule endoscopy technology. Major developments and product approvals have been conducted in capsule propulsion, battery technology, and optics to provide the basis for future research and clinical studies
Restraint: High R&D costs for technological developments and advancements
Developing and refining the technology for smart pills involves substantial R&D investments. The procedure requires designing and testing complex sensors, miniaturized cameras, wireless communication capabilities, and data analysis algorithms, which further contribute to the overall elevated cost of smart pills. Furthermore, the need for specialized equipment and trained healthcare professionals adds to the overall cost of implementing smart pill technology. These financial barriers may limit the widespread adoption of smart pills, particularly in resource-constrained healthcare systems. Although the technology is still in its early stages, it can be costly to manufacture and distribute, which may limit access for those who need it most.
Opportunity: Innovations in sensor technologies and wireless communication
Smart pills, equipped with sensors, microprocessors, and wireless communication features, have transformed the field of medicine. Innovations in miniaturization, extended battery life, and enhanced data processing capabilities have made these pills more efficient and accessible. Sensors have become smaller, lighter, and more efficient, allowing for their integration into pills that can be safely ingested. These miniature sensors can monitor physiological markers such as temperature, pressure, and pH levels in the body, which allows for continuous and real-time health data collection that was previously not possible. Modern sensors are now more sensitive and accurate than ever before, providing smart pills with more reliable data about a patient's health, from disease monitoring to diagnosis.
Challenge: Increased patient privacy and data security concerns
Data security in healthcare was already a main concern for patients and providers worldwide. In 2023, 548 healthcare data breaches were reported to the OCR, potentially impacting nearly 122 million individuals by compromising their protected health information. Integrating advanced technologies and sensors in smart pills raises worries about collecting, storing, and using personal health data. Smart pills generate and transmit sensitive health data, comprising medication adherence, physiological parameters, and potentially even real-time video or images from within the body
SMART PILLS MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Smart ingestible sensors to monitor internal health metrics and detect GI disorders | Real-time patient data, early diagnosis, and reduced need for invasive procedures |
 |
Capsule endoscopy systems for advanced gastrointestinal imaging. | High-resolution imaging, improved diagnostic accuracy, and enhanced patient comfort |
 |
360° panoramic capsule endoscopy to visualize the small intestine. | Comprehensive GI tract view, reduced blind spots, and enhanced detection rates |
 |
Wireless capsule endoscopy integrating motion control and advanced imaging. | Detailed visualization of GI tract with minimal discomfort and no sedation |
 |
Smart capsules for minimally invasive GI examination and data collection. | Lower risk procedures, cost-effective diagnostics, and faster patient recovery |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The smart pills market is shaped by a dynamic ecosystem involving manufacturers, healthcare providers, regulatory bodies, and patients. Key players such as Olympus Corporation, Medtronic, and CapsoVision, Inc. design and supply smart pills. These companies drive the market through continuous innovations in devices such as smart pills for non-invasive imaging of the GI tract, offering a less invasive alternative to traditional endoscopies or colonoscopies. Data security providers help ensure that the sensitive health data generated by these devices is kept secure, private, and compliant with regulatory requirements. The FDA, the European Medicines Agency (EMA), and other regulatory authorities oversee the approval, safety, and quality of smart pill products
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Smart Pills Market, By Disease Indications
By disease indications, the smart pills market is broadly segmented into Crohn’s disease, small bowel tumors, occult GI bleeding, celiac disease, and other disease indications. The occult GI bleeding segment accounted for the largest share in 2023 owing to the increasing disease prevalence, growing demand for non-invasive diagnostics, and rising technological advancements in smart pill technologies, which are expected to drive the adoption of smart pills in this segment during the forecast period. The endorsement of capsule endoscopy by the European Society of Gastrointestinal Endoscopy (ESGE) guidelines provides a standardized approach for healthcare professionals, enhancing the quality of care provided to patients. These guidelines focus on the importance of smart pills in the treatment of different GI conditions and rare diseases related to the small intestine. As a result, the growing demand for smart pills and other related technologies is driven by the rising utilization of capsule endoscopy for GI bleeding. The small bowel tumor is expected to grow at the highest CAGR during the forecast period due to advancements in sensor technology, growing emphasis on patient convenience, rising need for early diagnosis of tumors, and proper treatment
Smart Pills Market, By Target Area
By target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. In 2023, the large intestine target area accounted for the second largest share of smart pills market. Factors such as rising cases of colorectal cancer and requirement for applicable screening, diagnosis, and examining of inflammatory bowel diseases and other gastrointestinal diseases. The growing cases of colorectal cancer & colon cancer have contributed to the rising adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be difficult to visualize with traditional methods
Smart Pills Market, By Application
By application, smart pills market is bifurcated into capsule endoscopy, patient monitoring, and targeted drug delivery. In 2023, patient monitoring segment accounted for the second largest share of smart pills market. This is attributed to launch of innovative sensor technologies and the rising need for precise & accurate measurement of inner body temperatures. Increasing demand for streamlined integration is expected to enhance the adoption of smart pills due to expanded connectivity and compatibility with digital health systems
Smart Pills Market, By End Users
By end users, smart pills are divided into hospitals, diagnostic centers, outpatient settings (clinics, ambulatory care centers), and other end users. In 2023, the hospitals segment held the largest market share due to rising hospitalizations and surgical operations globally, poor medication adherence, and increasing demand for minimally invasive diagnostic monitoring devices. The non-invasive nature of smart pills, combined with their ability to enhance early detection & diagnosis, make them a lucrative substitute for hospitals seeking to advance patient care and address the growing burden of inflammatory bowel disease (IBD). According to the Chron’s and Colitis Foundation of America, as many as 70,000 new cases of inflammatory bowel disease (IBD) are diagnosed in the US annually. IBD, which includes Crohn’s disease and ulcerative colitis, affects roughly 1.6 million Americans, most of whom are diagnosed before age 35. Overall, the surge in IBD cases has prompted hospitals to embrace smart pills as a valuable tool in diagnostic procedures. The non-invasive nature of smart pills and their ability to enhance early detection and diagnosis makes them a lucrative alternative for hospitals seeking to improve patient care and address the increasing burden of IBD
REGION
Asia Pacific is registered the highest growth during the forecast period with significant CAGR in 2023
During forecast period, the Asia-pacific smart pills market is expected to grow at the highest CAGR. Factors which are driving this growth include increased in the presence of established vendors in the regional market and growing adoption of capsule endoscopy in countries such as China and India. The growing incidence of stomach cancer in Japan has created a rising demand for advanced diagnostic technologies such as capsule endoscopy. This non-invasive and patient-friendly method employs small, swallowable capsules equipped with cameras to capture specified images of the gastrointestinal tract
SMART PILLS MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMPANY EVALUATION MATRIX
In the smart pills market matrix, Medtronic (Star) leads with a dominant market share and a diversified smart pill portfolio, backed by strong clinical validation, global distribution, and deep integration with remote patient monitoring platforms. Its advanced capsule endoscopy and ingestible sensor technologies position it as the benchmark player for both diagnostics and digital health applications. Shangxian Minimal Invasive Inc. (Emerging Leader) is rapidly gaining traction with cost-efficient smart capsule solutions targeted at high-growth Asian markets, supported by localized manufacturing and increasing hospital adoption. While Medtronic continues to set industry standards through scale, R&D depth, and regulatory reach, Shangxian holds strong potential to move toward the leaders' quadrant as demand for affordable, minimally invasive GI diagnostics expands across developing healthcare systems.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Medtronic (US)
- Olympus Corporation (Japan)
- CapsoVision, Inc. (US)
- IntroMedic (Seoul)
- AnX Robotics (US)
- Shenzhen jifu Medical Technology Co., Ltd. (China)
- JINSHAN Science & Technology (Group) Co., Ltd. (China)
- etectRx (US)
- BodyCap (France)
- Check-Cap (Israel)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2023 (Value) | USD 0.61 Billion |
| Market Forecast in 2030 (Value) | USD 1.30 Billion |
| Growth Rate | CAGR of 11.2% from 2024-2030 |
| Years Considered | 2022-2030 |
| Base Year | 2023 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD Billion), Volume (Unit) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: SMART PILLS MARKET: GROWTH, SIZE, SHARE, AND TRENDS REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Need for competitive landscape insights beyond capsule endoscopy | Delivered detailed competitor profiling including drug-delivery and sensor-based capsule manufacturers | Enabled strategic product positioning and identification of partnership/acquisition opportunities |
| Require regulatory and reimbursement roadmap for multiple regions | Provided country-wise FDA/CE approval routes, reimbursement codes, and timelines for smart pill classes | Accelerated go-to-market planning and reduced compliance risks in target regions |
| Looking for new growth avenues beyond hospitals and diagnostics | Identified emerging end-user segments (sports medicine, telehealth, pharma delivery ecosystems) | Helped expand TAM and align product roadmap with non-traditional verticals |
| Need to understand technological evolution and investment areas | Delivered tech roadmap covering AI-integrated ingestibles, microrobotics, and digital twin-based diagnostics | Supported R&D prioritization and investor communication with future-proof innovation narrative |
| Demand for actionable market model and sizing validation | Built dynamic forecasting model with inputs across regions, use-cases, and capsule types (imaging, drug) | Drove data-backed decision-making for product allocation, resource planning, and investor pitching |
RECENT DEVELOPMENTS
- January 2025 : CapsoVision, Inc. (US) received FDA clearance for CapsoCam Plus for use in pediatric patients aged two and older. This milestone allows children to benefit from the ease and precision of capsule endoscopy, offering a non-invasive, comfortable diagnostic option that minimizes the stress typically associated with traditional endoscopy procedures
- January 2024 : AnX Robotics (US) received FDA clearance for expanded indications of its NaviCam Small Bowel Video Capsule Endoscopy (SB) for both adults and children aged 2 years and older. This important milestone, along with the recent FDA clearance of ProScan, the groundbreaking AI-assisted reading tool for Small Bowel Video Capsule Endoscopy (VCE), firmly positions NaviCam SB as the most advanced technology in small bowel video capsule endoscopy
- March 2023 : etectRx (US) announced that its digital pill, the ID-Cap System, has surpassed 10,000 ingestions, a significant milestone for the company with a reputation for demonstrating strong results and providing data to accurately track patients’ adherence to their oral medications
- COLUMN 'A' SHOULD BE IN TEXT FORMAT AND NOT DATE FORMAT :
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study involved three major activities in estimating the size of the smart pills market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the smart pills market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 3: Tiers of companies are defined on the basis of their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the smart pills market. These methods were also used extensively to estimate the size of various subsegments in the market.
Data Triangulation
After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the smart pills market.
Market Definition
"Smart pills" refer to miniature electronic devices that are shaped and designed like pharmaceutical capsules, but are equipped with advanced functions such as sensing, imaging, and drug delivery. These devices may incorporate biosensors, image sensors, pH sensors, or chemical sensors. When ingested, they traverse the gastrointestinal tract to gather valuable information that is otherwise challenging to obtain. Unlike implantable or wearable sensors, these ingestible sensors can be easily eliminated from the body after use.
Stakeholders
- Smart pills manufacturers
- Healthcare providers (physician practices, diagnostic centers, and outpatient clinics)
- Government bodies
- Software Developers and Data Analysts
- Corporate entities
- Pharmaceutical companies
- Hospitals
- Research and consulting firms
- Venture Capitalists
Report Objectives
- To define, describe, and forecast the smart pills market based on the application, target area, disease indication, end user, and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall smart pills market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders.
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa.
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & enhancements, agreements, collaborations, partnerships, and expansions in the smart pills market.
- To benchmark players within the market using the proprietary "Company Evaluation Quadrant " framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Smart Pills Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Smart Pills Market